NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Company (BMY) said Thursday that it has discontinued development of BMS-986094, a nucleotide polymerase inhibitor that was in Phase II development for the treatment of hepatitis C.
The company had suspended the Phase II study on August 1, after an initial case of heart failure which subsequently resulted in death. Nine patients have been hospitalized to date.
Bristol-Myers is working in close collaboration with the FDA and clinical study investigators to conduct ongoing, comprehensive assessments and close follow-up of all BMS-986094 study patients.
While the cause of these unexpected events, which involve heart and kidney toxicity, has not been definitively established, the company has determined that it is in the best interest of patients to halt development of BMS-986094.
Copyright RTT News/dpa-AFX